Therapeutic strategies for acute myeloid leukemia (AML) remain limited by toxicity and suboptimal efficacy, highlighting the need for novel agents with improved safety profiles. AML is an aggressive hematologic malignancy driven by mutations in hematopoietic stem cells (HSCs) or myeloid progenitors that lead to uncontrolled proliferation and accumulation of immature myeloid cells. In this study, we investigated the therapeutic potential of a 70% tocotrienol-enriched fraction isolated from Bixa orellana L. for AML treatment by evaluating its effects on AML cells and in leukemic mouse models.